Geode Capital Management
KYTX icon

Geode Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

Geode Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.35M Buy
1,049,430
+625,604
+148% +$5.55M ﹤0.01% 2584
2026
Q1 		$3.66M Buy
423,826
+157,424
+59% +$1.31M ﹤0.01% 2893
2025
Q4 		$2.51M Sell
266,402
-11,927
-4% -$88.5K ﹤0.01% 3080
2025
Q3 		$1.67M Sell
278,329
-9,272
-3% -$37.1K ﹤0.01% 3240
2025
Q2 		$883K Sell
287,601
-276,373
-49% -$684K ﹤0.01% 3365
2025
Q1 		$1.09M Buy
563,974
+24,292
+5% +$71.8K ﹤0.01% 3277
2024
Q4 		$2.02M Buy
539,682
+96,370
+22% +$462K ﹤0.01% 3119
2024
Q3 		$2.17M Buy
443,312
+70,714
+19% +$545K ﹤0.01% 3097
2024
Q2 		$2.79M Buy
372,598
+200,362
+116% +$3.06M ﹤0.01% 3012
2024
Q1 		$4.28M Buy
+172,236
New +$4.81M ﹤0.01% 2779

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management's KYTX Position: Q2 2026 in Review

Geode Capital Management increased its Kyverna Therapeutics (KYTX) stake by 148% in Q2 2026, buying an estimated $5.55M and bringing the position to 1,049,430 shares worth $9.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2584.

Geode Capital Management first reported a position in KYTX in Q1 2024 and has held it in 10 quarters since. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Geode Capital Management held 1,049,430 shares of Kyverna Therapeutics worth $9.35M as of Q2 2026.
  • Geode Capital Management bought 625,604 Kyverna Therapeutics shares in Q2 2026, an estimated $5.55M.
  • Kyverna Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2584 holding.
  • Geode Capital Management first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.